HIV-1 capsid inhibitor; oral or subcutaneous, part of long-acting prevention/treatment
UNAids warns that funding cuts and tightening civic space threaten progress against HIV. Six-month lenacapavir injections are rolling out in South Africa, with early results showing promise but concerns over access and equity persist as external aid declines.
The United States has begun a phased drawdown of PEPFAR in South Africa, citing policy disagreements and a belief that South Africa can sustain its HIV programs. Pretoria says it will continue treatment with domestic funding, while UN meetings seek clarity on future donor support.
Malawi has launched Lenacapavir, a twice-yearly HIV prevention injection, offering hope for reducing new infections. Advocates warn that information gaps and stigma remain challenges as communities adapt to long-acting prevention.
An international trial shows weekly HIV medication is as effective as daily doses, potentially reducing stigma and treatment burden. In Ghana, authorities reassure continued ARV availability amid distribution concerns. Nigerian and Ugandan health updates highlight high suppression rates and ongoing prevention efforts.